Paraxanthine

Caffeine's main active metabolite, sold direct as ENFINITY — what your liver makes anyway when you drink coffee, but skipping the parent molecule means you get the alerting/ergogenic effects without the theophylline-driven HR/BP load and with a shorter (~3-4h) half-life that's friendlier to Dylan's midnight-bedtime migration project. The Yoo 2021 RCT and follow-up Jagim/Kreider 2024 trials show caffeine-matched cognition + reaction time + ergogenic effect at 200mg, with smaller HR rise and less self-reported jitter. For Dylan's caffeine-naive 20yo profile, OPTIONAL-ADD — a sensible cleaner alternative for late-day cognitive work or pre-MMA, but caffeine + 1:2 theanine probably does 90% of the same thing for a tenth the price. Worth a 30-day trial PRN, not a daily core add.

Paraxanthine (1,7-dimethylxanthine, "17DMX") is a methylxanthine you already make. When you drink caffeine, hepatic CYP1A2 demethylates the 3-position methyl group, producing paraxanthine — which accounts for ~80% of caffeine's downstream metabolism in humans and is responsible for a substantial share of caffeine's CNS effect (estimates range from 60% to 80% depending on the half-life model used). The other two minor metabolites — theophylline (~10%) and theobromine (~10%) — are what drive most of caffeine's peripheral cardiovascular load (theophylline is a stronger PDE inhibitor and bronchodilator than caffeine itself; theobromine has a longer half-life and contributes to delayed CV effects).

Direct paraxanthine dosing skips the theophylline + theobromine secondary metabolism, which is the central mechanistic argument for cleaner peripheral profile.

Primary action — A1 + A2A adenosine receptor antagonism (the "alerting" face):

• Like caffeine, paraxanthine is a non-selective antagonist at A1 and A2A adenosine receptors. Block these → glutamate, ACh, NE, DA disinhibition across cortex/striatum → alertness, attention, reaction time, motor activation. Same final-common-path mechanism as caffeine.
• Receptor binding affinity: Paraxanthine has Ki values in roughly the same range as caffeine at A1 (low μM) and A2A (low μM). Some receptor binding studies suggest paraxanthine is slightly A2A-leaning relative to caffeine's more balanced A1/A2A profile — which would predict marginally more "motivational/motor-activation" feel and marginally less "pure cortical alerting" feel. In practice, the subjective difference is small enough that most users describe paraxanthine as feeling like clean caffeine.
• Why no jitter / less peripheral activation: The cleaner side-effect profile is NOT primarily about A2A selectivity (caffeine and paraxanthine are both non-selective). It's about the absence of theophylline + theobromine secondary metabolism: when you dose caffeine, your peripheral tissues see caffeine + theophylline + theobromine simultaneously over 4-8 hours; when you dose paraxanthine, you see paraxanthine alone, cleared in 3-4 hours, with no theophylline-driven bronchodilation/cardiac stimulation pile-up.

Secondary actions:

• Weak PDE inhibition at supraphysiologic doses (>500-1000mg) — same as caffeine, negligible at 200-300mg dosing.
• Ryanodine receptor Ca2+ release in skeletal muscle — relevant only at very high concentrations.
• Cyclic GMP-PDE5 inhibition — paraxanthine is a slightly stronger PDE5 inhibitor than caffeine in vitro, which has been speculated to contribute to its ergogenic profile (vasodilation, NO availability), but the in-vivo signal at standard doses is small.

Pharmacokinetic differences vs caffeine:

• Half-life ~3-4 hours in healthy adults (caffeine ~5h average, ranging 2-10h across CYP1A2 phenotypes). Faster taper.
• Cleared primarily via demethylation to 1-methylxanthine and then 1-methyluric acid (not via CYP1A2 — paraxanthine is the product of CYP1A2, not a substrate of it for further methylation). This is a real practical advantage: paraxanthine clearance is independent of CYP1A2 phenotype, so slow caffeine metabolizers (CYP1A2 CC, ~10-15% of Caucasians) don't experience prolonged paraxanthine half-life the way they experience prolonged caffeine half-life.
• No CYP1A2-mediated drug interactions on the metabolism side — smokers, cruciferous-veg eaters, oral-contraceptive users get the same paraxanthine kinetics regardless of their CYP1A2 induction state.

Tolerance mechanism: Same as caffeine — chronic dosing produces adenosine A1 + A2A receptor upregulation in cortex and striatum within 7-14 days. There is NO mechanistic reason to expect paraxanthine to escape caffeine-style tolerance, and Compound Solutions' marketing claim that paraxanthine "doesn't build tolerance" is mechanistically implausible. Treat tolerance/cycling assumptions identically to caffeine.